Trials / Completed
CompletedNCT00057616
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 274 (planned)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects are treated in repeating 4 week cycles.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 |
Timeline
- Start date
- 2002-10-01
- Completion
- 2005-07-15
- First posted
- 2003-04-07
- Last updated
- 2019-11-08
Locations
49 sites across 9 countries: Australia, Estonia, Germany, Latvia, Lithuania, Netherlands, South Africa, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00057616. Inclusion in this directory is not an endorsement.